Pasithea Therapeutics’ (NASDAQ: KTTA) CEO, Dr. Tiago Reis Marques, a psychiatrist at one of the top psychiatry centers in the world, a fellow at Imperial College London and a lecturer at the Institute of Psychiatry, King’s College London, was featured in a recent Forbes article. The piece, titled “You May Soon Find Mental Health Help from Psychedelic Drug-Assisted Psychotherapy in the Metaverse,” discusses record levels of mental health issues driven by the pandemic, social unrest, partisan politics, cable news, social media and Russia’s war against Ukraine. To learn about ways to help with this mental health epidemic, the article’s author and Forbes’ senior contributor, Jack Kelly, spoke with Dr. Marques. He shared the promising innovation of psychedelic, drug-assisted psychotherapy—the medically approved use of MDMA, psilocybin and LSD as a component of elevated psychotherapy programs.
“With these new clinics, we will broaden our London footprint and start offering pharmacy services and new treatment options, bringing important and novel mental health therapies to an ever-growing number of people,” said Dr. Marques. “In addition to pharmacy services, our London clinics will offer other psychiatric treatment therapies, including repeated transcranial magnetic stimulation in addition to IV ketamine.”
To view the full article, visit https://ibn.fm/ojeWy
About Pasithea Therapeutics Corporation
Pasithea Therapeutics is at the forefront of research into mental health and brain disorders. The biotech company is aiming to solve one of the world’s biggest clinical problems: brain disorders. The long-term aim is to translate research into clinic-ready drugs. Pasithea’s primary focus is on drug development with the goal of its scientific team to develop new medications that provide better and longer-lasting results for individuals with mental health issues. For more information about the company, visit www.Pasithea.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.